We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




AI-Enabled Digital Pathology Scanner Provides Real-Time Predictive Analysis

By LabMedica International staff writers
Posted on 01 Jun 2022
Print article
Image: OS-SiA: Digital Pathology Scanner with AI (Photo courtesy of OptraSCAN)
Image: OS-SiA: Digital Pathology Scanner with AI (Photo courtesy of OptraSCAN)

A digital pathology scanner has inbuilt intelligence to scan, index and analyze pathological samples simultaneously, allowing the end-user to view the whole slide scanned image along with analyzed output as an overlay during their review process.

The OS-SiA AI-enabled digital pathology scanner from OptraSCAN, Inc. (San Jose, CA, USA) automatically identifies specimens to scan and simultaneously analyzes the tissue or cell area being scanned. OS-SiA is the industry's first AI-enabled digital scanner that will provide real-time predictive analysis and actionable insights.

OS-SiA can be embedded in the existing series of its cloud-enabled brightfield scanners namely OS-Lite & OS-Ultra. The custom algorithms provide real-time ROI detection while scanning, cell quantification for IHC/HNE markers, and morphological measurements built using the core library. The whole slide image can be viewed in a local / web-based / cloud-based image viewer. The deep learning computational module is provided for self-learning in the scanning device. OptraSCAN has been granted a US patent for its OS-SiA digital pathology scanner for scanning, indexing and analyzing of the tissue area at the same time.

"Currently, the digital pathology slide scanners are restricted to partial or whole slide image acquisition and digitization into an image. Our next-generation scanner OS-SiA scans and analyzes simultaneously eliminating the need for additional processing applications," said Abhi Gholap, Founder & CEO, OptraSCAN. "This patent highlights our constant efforts to improve the adoption of digital pathology solutions and support the pathology community."

"This is the kind of breakthrough we need to accelerate the adoption of digital pathology, simultaneous scanning and analysis will help pathologists make faster decisions and improve patient outcomes," added Dr. Zu-Hua Gao MD, Medical Advisor at OptraSCAN and Chair - Pathology, University of British Columbia.

Related Links:
OptraSCAN, Inc. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: A false color scanning election micrograph of lung cancer cells grown in culture (Photo courtesy of Anne Weston)

AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell

Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.